The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 401–500 of 1,025
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C. A., Miller, B. L., & Jagust, W. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 153
Yang, C., Chiu, M., Chen, T., Chang, H.-L., Liu, B.-H., & Yang, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170810 · Cited by 143
Alzheimer's Disease and the Amyloid β Protein
Small, D. H., & McLean, C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730443.x · Cited by 146
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation
Crowe, A., James, M. J., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., & Brunden, K. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436006 · Cited by 143
Marks, S. M., Lockhart, S. N., Baker, S. L., & Jagust, W. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3769-16.2017 · Cited by 144
The Neuropathological Diagnosis of Alzheimer’s Disease: Clinical-Pathological Studies
Hyman, B. T. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00066-3 · Cited by 145
Self-citationAGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE
Petersen, R. C. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70226-7 · Cited by 144
Bouras, C., Hof, P. R., & Morrison, J. H. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90305-5 · Cited by 142
Götz, J., Schild, A., Hoerndli, F. J., & Pennanen, L. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.07.013 · Cited by 146
Crimins, J. L., Rocher, A. B., & Luebke, J. I. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1038-9 · Cited by 142
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 141
Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia
Samuel, W., Terry, R. D., DeTeresa, R. M., Butters, N., & Masliah, E. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540200048015 · Cited by 142
Castellani, R. J., Lee, H., Siedlak, S. L., Nunomura, A., Hayashi, T., Nakamura, M., Zhu, X., Perry, G. L., & Smith, M. A. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1151 · Cited by 140
Santa‐María, I., Varghese, M., Ksiȩżak-Reding, H., Dzhun, A., Wang, J., & Pasinetti, G. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323279 · Cited by 145
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
Iqbal, K., Alonso, A. D. C., Gong, C., Khatoon, S., Pei, J. ‐., Wang, J. Z., & Grundke, I. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_15 · Cited by 143
Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer’s disease
Branca, C., Ferreira, E., Nguyen, T.-V., Doyle, K., Caccamo, A., & Oddo, S. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx361 · Cited by 139
Brain cholinergic vulnerability: Relevance to behavior and disease
McKinney, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.019 · Cited by 140
Reynolds, M. R., Reyes, J. F., Fu, Y., Bigio, E. H., Guillozet-Bongaarts, A. L., Berry, R. W., & Binder, L. I. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2143-06.2006 · Cited by 143
Striatal β-Amyloid Deposition in Parkinson Disease With Dementia
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., & Pearce, R. K. B. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816362aa · Cited by 144
Alescio-Lautier, B., Michel, B., Herrera, C., Ahmadi, A. E., Chambon, C., Touzet, C., & Paban, V. (2007) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.04.033 · Cited by 147
Intercellular Spread of Protein Aggregates in Neurodegenerative Disease
Davis, A. A., Leyns, C. E. G., & Holtzman, D. M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062636 · Cited by 131
Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138
Mechanobiology of the brain in ageing and Alzheimer's disease
Hall, C. M., Moeendarbary, E., & Sheridan, G. K. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14766 · Cited by 140
Spires-Jones, T. L., de Calignon, A., Matsui, T., Zehr, C., Pitstick, R., Wu, H.-Y., Osetek, J. D., Jones, P. B., Bacskai, B. J., Feany, M. B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3072-08.2008 · Cited by 137
Self-citationSpillantini, M. G., Crowther, R. A., & Goedert, M. (1996) · Acta Neuropathologica · doi:10.1007/s004010050487 · Cited by 160
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 142
Ma, Q., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Kiosea, N., Nazari, S., Chen, P. P., Nothias, F., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3439-13.2014 · Cited by 135
A New Molecular Link between the Fibrillar and Granulovacuolar Lesions of Alzheimer's Disease
Ghoshal, N., Smiley, J. F., DeMaggio, A. J., Hoekstra, M. F., Cochran, E. J., Binder, L. I., & Kuret, J. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65219-4 · Cited by 137
Thal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
Palmer, A. M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.007 · Cited by 136
Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S. S., Sperling, R. A., Dale, A. M., & Initiative, A. D. N. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 139
Tau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Ghebremedhin, E., Schultz, C., Braak, E., & Braak, H. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6860 · Cited by 133
LRP in Amyloid‐β Production and Metabolism
Bu, G., Cam, J. A., & Zerbinatti, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1377.005 · Cited by 141
Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy
Bandyopadhyay, B., Li, G., Yin, H., & Kuret, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700192200 · Cited by 139
Wallin, A., Blennow, K., Andreasen, N. C., & Minthon, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090631 · Cited by 142
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Sämgård, K., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., & Londos, E. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2353 · Cited by 135
Synaptic remodeling during aging and in Alzheimer's disease
Masliah, E., Crews, L., & Hansen, L. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s311 · Cited by 132
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Tauopathy: A common mechanism for neurodegeneration and brain aging
Saha, P., & Sen, N. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.01.007 · Cited by 134
Selenica, M. L., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707471 · Cited by 135
Neuropathology of Alzheimer disease: pathognomonic but not pathogenic
Castellani, R. J., Lee, H., Zhu, X., Nunomura, A., Perry, G. L., & Smith, M. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0071-y · Cited by 133
Traffic at the intersection of neurotrophic factor signaling and neurodegeneration
Salehi, A., Delcroix, J.-D., & Mobley, W. C. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)00038-3 · Cited by 131
Insulin dysfunction and Tau pathology
Khoury, N. B. E., Gratuze, M., Papon, M.-A., Bretteville, A., & Planel, E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00022 · Cited by 133
Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia
Gefen, T. D., Gasho, K., RADEMAKER, A. W., Lalehzari, M., Weıntraub, S., Rogalski, E. J., Wieneke, C., Bigio, E. H., Geula, C., & Mesulam, M. M. (2012) · Brain · doi:10.1093/brain/aws076 · Cited by 135
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 135
The deterioration of semantic memory in Alzheimer's disease.
Salmon, D. P., Butters, N., & Chan, A. S.-Y. (1999) · Canadian Journal of Experimental Psychology/Revue canadienne de psychologie expérimentale · doi:10.1037/h0087303 · Cited by 140
Leveugle, B., Spik, G., Perl, D. P., Bouras, C., Fillit, H. M., & Hof, P. R. (1994) · Brain Research · doi:10.1016/0006-8993(94)90202-x · Cited by 131
Moceri, V. M., Kukull, W. A., Emanual, I., van Belle, G., Starr, J. R., Schellenberg, G. D., McCormick, W. C., Bowen, J. D., Teri, L. L., & Larson, E. B. (2001) · Epidemiology · doi:10.1097/00001648-200107000-00007 · Cited by 132
A plasticity-based theory of the pathogenesis of Alzheimer's disease.
MESULAM, M. ‐. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05559.x · Cited by 130
Bancher, C., Jellinger, K., Lassmann, H., Fischer, P., & Leblhuber, F. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02189115 · Cited by 130
Saitoh, M., Kunitomo, J., Kimura, E., Iwashita, H., Uno, Y., Onishi, T., Uchiyama, N., Kawamoto, T., Tanaka, T., Mol, C. D., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900647e · Cited by 130
Pathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 137
Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease
Kawamoto, E. M., Munhoz, C. D., Glezer, I., Bahia, V. S., Caramelli, P., Nitríni, R., Gorjão, R., Curi, R., Scavone, C., & Marcourakis, T. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.011 · Cited by 129
Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 129
Functional connectivity changes differ in early and late-onset alzheimer's disease
Gour, N., Félician, O., Didic, M., Koric, L., Guériot, C., Chanoine, V., Sylviane Confort-gouny, A., Guye, M., Ceccaldi, M. P., & Ranjeva, J. (2013) · Human Brain Mapping · doi:10.1002/hbm.22379 · Cited by 129
[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128
Patterson, K. R., Ward, S. M., Combs, B., Voss, K., Kanaan, N. M., Morfini, G. A., Brady, S. T., Gamblin, T. C., & Binder, L. I. (2011) · Biochemistry · doi:10.1021/bi2009147 · Cited by 128
Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 128
Hsp70 Inhibits the Nucleation and Elongation of Tau and Sequesters Tau Aggregates with High Affinity
Kundel, F., De, S., Flagmeier, P., Horrocks, M. H., Kjærgaard, M., Shammas, S. L., Jackson, S., Dobson, C. M., & Klenerman, D. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b01039 · Cited by 130
Miao, J., Shi, R., Li, L., Chen, F., Zhou, Y., Tung, Y. C., Hu, W. H., Gong, C., Iqbal, K., & Liu, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00034 · Cited by 125
Cdk5: Multitasking between physiological and pathological conditions
Lopes, J. P., & Agostinho, P. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.006 · Cited by 134
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., Marotta, R., Xu, H., & Gasparini, L. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0082-7 · Cited by 126
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 131
Corrigan, F., Horrobin, D., Skinner, E., Besson, J. O., & Cooper, M. (1998) · International Journal of Biochemistry and Cell Biology · doi:10.1016/s1357-2725(97)00125-8 · Cited by 102
Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro
Shin, R. W., Lee, V., & Trojanowski, J. Q. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-11-07221.1994 · Cited by 126
Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy
Yue, M., Hanna, A., Wilson, J., Roder, H. M., & Janus, C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.006 · Cited by 125
Lee, J., Blennow, K., Andreasen, N., Laterza, O., Modur, V., Olander, J. V., Gao, F., Ohlendorf, M. F., & Ladenson, J. H. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104497 · Cited by 127
Synaptic alterations in the rTg4510 mouse model of tauopathy
Kopeikina, K. J., Polydoro, M., Tai, H., Yaeger, E., Carlson, G. A., Pitstick, R., Hyman, B. T., & Spires‐Jones, T. L. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.23234 · Cited by 129
Self-citationImmunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Cited by 125
Leptin Dysfunction and Alzheimer’s Disease: Evidence from Cellular, Animal, and Human Studies
McGuire, M. J., & Ishii, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0282-7 · Cited by 129
The role of amyloid oligomers in neurodegenerative pathologies
Wells, C., Brennan, S. E., Keon, M., & Ooi, L. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.113 · Cited by 131
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M. ‐. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14406 · Cited by 125
Walton, J. R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132204 · Cited by 126
Güntekin, B., Saatçı, E., & Yener, G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.028 · Cited by 123
Small-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomović, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 124
Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
Zhou, Y., Shi, J., Chu, D., Hu, W. H., Guan, Z., Gong, C., Iqbal, K., & Liu, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00027 · Cited by 130
The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 127
Paasila, P. J., Davies, D., Kril, J. J., Goldsbury, C. S., & Sutherland, G. T. (2019) · Brain Pathology · doi:10.1111/bpa.12717 · Cited by 120
Meyer, P., Binette, A. P., Gonneaud, J., Breitner, J. C. S., Villeneuve, S., & ADNI Investigators (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4749 · Cited by 126
Microglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Ávila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 134
Hippocampal Shape Analysis of Alzheimer Disease Based on Machine Learning Methods
Li, S., Shi, F., Pu, F., Li, X., Jiang, T., Xie, S., & Wang, Y. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0620 · Cited by 127
The Role of Synapsins in Neurological Disorders
Mirza, F. J., & Zahid, S. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0201-7 · Cited by 127
Cieri, D., Vicario, M., Vallese, F., D’Orsi, B., Berto, P., Grinzato, A., Catoni, C., Stefani, D. D., Rizzuto, R., Brini, M., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.011 · Cited by 124
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model
Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122
Zheng, W., Kar, S., Doré, S., & Quirion, R. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_17 · Cited by 122
Arendt, T., Brückner, M. K., Gertz, H.-J., & Marcova, L. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00509-5 · Cited by 122
Arendt, T., Holzer, M., Grossmann, A., Zedlick, D., & Brückner, M. K. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00146-a · Cited by 123
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
Rudrabhatla, P., Jaffe, H., & Pant, H. C. (2011) · The FASEB Journal · doi:10.1096/fj.11-181297 · Cited by 121
Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’
Castellani, R. J., & Smith, M. A. (2011) · The Journal of Pathology · doi:10.1002/path.2885 · Cited by 129
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
Padmanabhan, J., Levy, M. M., Dickson, D. W., & Potter, H. (2006) · Brain · doi:10.1093/brain/awl255 · Cited by 124
Diagnostic accuracy of alzheimer’s disease: A neuropathological study
Kosunen, O., Soininen, H. S., Paljärvi, L., Heinonen, O., Talasniemi, S., & Riekkinen, P. J. (1996) · Acta Neuropathologica · doi:10.1007/s004010050412 · Cited by 119
Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
López, A., Lee, S. E., Wojta, K. J., Ramos, E. M., Klein, E., Chen, J., Boxer, A. L., Gorno‐Tempini, M. L., Geschwind, D. H., Schlotawa, L., et al. (2017) · Brain · doi:10.1093/brain/awx005 · Cited by 120
Assessing neuronal networks: Understanding Alzheimer's disease
Bokde, A. L. W., Ewers, M., & Hampel, H. J. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.06.004 · Cited by 120
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
